Improving immune cell infiltration in COAD by developing drugs that act on the CXC chemokine-VEGFA network or CXC chemokines and VEGFA-related regulatory targets may serve as a viable therapeutic oncology approach. This evidence concerns the gene VEGFA and colon adenocarcinoma.